Scientists at SENS Research Foundation led by Dr. Tesfahun (Tes) Dessale Admasu have just published their exciting new senolytic strategy to destroy a wider range of senescent cells than has up to now been possible. One of the ways that senescent cells accumulate with age is when one (primary) senescent cell turns a neighboring cell senescent through its SASP secretion. Dr. Admasu discovered that conventional senolytic drugs such as Navitoclax and Dasatinib are much less effective at killing off these “secondary” senescent cells than they are against
the better-known primary senescent cells.
Dr. Admasu then identified a new strategy that is effective in destroying both primary and secondary senescent cells, by targeting senescent cells’ abnormal iron accumulation. This new approach holds the promise to clear out senescent cells that would otherwise escape senolytic therapies, including potentially populations of cells that might be especially important to the aging of particular tissues or specific diseases of aging.
Dr. Admasu and other SRF scientists are now testing these new senolytics in aging mice to confirm their safety and senolytic potency in vivo, and will then identify their health benefits; we’ll keep you posted!
Link to publication: